// App-Quantinova.ai

112 : Phase II study of the efficacy of abirateron acetate with dutasteride for castration-resistant prostate cancer.

Researchers

Presenter

  • Hideyasu Matsuyama

Principal Investigators

  • Masaki Shiota

  • Kojiro Tashiro

  • Hiromi Kanji

  • Shizuyo Horiyama

  • Masatoshi Eto

  • Shin Egawa

  • Jun Haginaka

  • Ryo Inoue

  • Nishinomiya

Medical Centers

  • Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan

  • Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

  • The Jikei University School of Medicine, Tokyo, Japan

  • School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan

  • Department of Surgery and Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

  • Yamaguchi University Graduate School of Medicine, Ube, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Dutasteride

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Single Arm

  • Prospective

Phase

  • II

Study Id's

  • UMIN000027795

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved